Thymosin alpha-1 is a 28-amino-acid acetylated peptide originally isolated from bovine thymus tissue (Goldstein et al., 1972) and subsequently synthesised. It is registered as a medicinal product (Zadaxin) in over 35 countries for indications including chronic hepatitis B, hepatitis C and as an adjunctive therapy for vaccine response in immunocompromised patients. Its central research interest is in immune modulation: thymosin alpha-1 promotes T-cell maturation and helper T-cell function, with documented effects on dendritic cell maturation and Toll-like receptor signalling. The compound has been studied across infectious disease, oncology, autoimmune and post-surgical research lines.
Thymosin alpha-1 acts primarily through Toll-like receptor 9 (TLR9) and TLR2 on dendritic cells and pDC populations, driving maturation of antigen-presenting cells and downstream activation of T-helper-1 (Th1) immune responses. In parallel, it promotes thymic T-cell maturation — restoring the precursor pool that declines with age and immunosenescence.
Published research documents upregulation of IFN-α, IL-2 and IL-12 production from activated immune cells, alongside enhanced NK-cell cytotoxicity in preclinical assays. The compound has been studied in the context of impaired vaccine response (where co-administration improves seroconversion in immunocompromised cohorts), chronic viral hepatitis (the approved Zadaxin indications), and oncology adjunct research.
Across these indications the research framing is "immune-restoration" rather than "immune-suppression" — thymosin alpha-1 enhances response rather than blunting it, which is unusual for a peptide with a multi-decade clinical track record.
Thymosin alpha-1 holds regulatory approval as Zadaxin in over 35 countries for chronic hepatitis B and C. Published clinical research documents improved virologic response rates when combined with interferon-α versus interferon monotherapy. The compound is most commonly studied as an adjunct to standard antiviral protocols rather than as monotherapy.
Outside the approved indications, thymosin alpha-1 has been investigated in HIV (improvements in CD4+ counts in published Phase 2 trials), cytomegalovirus reactivation post-transplant, and acute respiratory infections including the published COVID-19 trial readouts.
Multiple Phase 2/3 trials have studied thymosin alpha-1 as an adjunct to chemotherapy or immunotherapy in melanoma, hepatocellular carcinoma and non-small-cell lung cancer. The research framing is immune-reconstitution and durable response — preserving T-cell competence through cycles of chemotherapy.
In vaccine response research, thymosin alpha-1 has been studied as a co-administration adjuvant in elderly and immunocompromised populations, where seroconversion rates to influenza and hepatitis B vaccines have been reported to improve in published trials.